Northwestern Turns CRISPR-Cas9 Into Spherical Nucleic Acid to Reach Inaccessible Tissues
Northwestern scientists have repackaged CRISPR-Cas9 as a spherical nucleic acid — a structural trick that lets gene-editing machinery penetrate tissues that have resisted every prior delivery method.
Explanation
CRISPR-Cas9 is the molecular scissors that can cut and rewrite DNA. The problem has never really been the scissors — it's getting them inside the right cells without the body destroying them first. Most delivery methods, like viral vectors or lipid nanoparticles, struggle with certain tissue types: skin, the brain, solid tumors, and others with dense or protective barriers.
Northwestern's fix: reshape the Cas9 protein itself into a spherical nucleic acid (SNA). SNAs are nanoscale spheres coated in a dense, radially arranged shell of DNA or RNA strands. That geometry isn't cosmetic — it changes how cells recognize and absorb the particle. SNAs are taken up efficiently by almost any cell type through a receptor-mediated process called scavenger receptor endocytosis, bypassing many of the barriers that stop conventional delivery vehicles cold.
By converting Cas9 into an SNA, the team essentially gave CRISPR a universal passport. The construct can now travel deeper into tissues and enter cell types that were previously off-limits for practical gene editing.
Why does this matter now? Delivery has been the bottleneck quietly killing otherwise promising CRISPR therapies in the clinic. Fixing the scissors was the easy part; getting them to the right address, at scale, without triggering an immune response, is where most programs stall. A delivery platform that works across tissue types doesn't just improve existing therapies — it reopens the target list for diseases that were written off as too hard to reach.
The immediate question is how this performs in vivo at therapeutic doses, and whether the SNA format introduces its own immunogenicity or off-target risks. Those answers will determine whether this is a platform shift or a clever proof of concept.
CRISPR-Cas9's clinical ceiling has been set less by editing precision than by delivery physics. Viral vectors (AAV, lentivirus) carry payload size limits and immunogenicity baggage; lipid nanoparticles (LNPs) dominate current approvals but show strong liver tropism and inconsistent performance in immunoprivileged or structurally dense tissues. Northwestern's SNA reformulation attacks this directly.
Spherical nucleic acids — a platform pioneered in Chad Mirkin's lab at Northwestern — exploit scavenger receptor-mediated endocytosis, a pathway active across virtually all mammalian cell types. The dense radial oligonucleotide shell confers nuclease resistance, suppresses innate immune activation (relative to linear nucleic acids), and drives cellular uptake without a transfection agent. Prior SNA work demonstrated efficacy in skin penetration and CNS delivery — tissue classes where LNPs underperform badly.
The new work extends SNA architecture to the Cas9 protein complex itself, not just guide RNA cargo. This is mechanistically non-trivial: Cas9 is a ~160 kDa protein that must remain conformationally intact and retain nuclease activity after surface conjugation and endosomal transit. Successfully threading that needle suggests the conjugation chemistry preserves the RNP (ribonucleoprotein) complex's functional geometry — a detail the field will want to scrutinize closely.
The tissue-access claim is the headline, but the more durable implication is target expansion. Diseases of the skin (genodermatoses), CNS (neurodegeneration, glioblastoma), and solid tumors have been structurally underserved by current CRISPR delivery. If SNA-Cas9 clears in vivo efficacy and tolerability bars in those compartments, it redraws the addressable disease map for base editing and prime editing payloads as well — both of which could in principle be adapted to the same SNA chassis.
Open questions worth tracking: in vivo editing efficiency versus LNP benchmarks in liver (the current gold standard comparator); immunogenicity profile of the protein-SNA conjugate after repeat dosing; and whether the manufacturing process scales without prohibitive cost. The falsifier here is straightforward — if tissue penetration gains come with off-target editing rates above the ~0.1% threshold that clinical programs typically require, the platform advantage collapses. Watch for IND-enabling studies within 18–24 months if the in vivo data holds.
Reality meter
Why this score?
Trust Layer Score basis
A detailed evidence breakdown is being added. For now, the score basis is the source list below and the reality meter above.
- 46 sources on file
- Avg trust 42/100
- Trust 40–95/100
Time horizon
Community read
Glossary
- Spherical nucleic acids (SNAs)
- A nanoparticle platform consisting of a dense shell of oligonucleotides arranged radially around a core, which enhances cellular uptake, resists degradation, and reduces immune activation compared to linear nucleic acids.
- Lipid nanoparticles (LNPs)
- Spherical particles composed of lipids that encapsulate and deliver genetic material to cells, currently the dominant delivery method for CRISPR therapies but with limitations in reaching certain tissues like the brain and dense solid tumors.
- Ribonucleoprotein (RNP) complex
- A functional unit consisting of RNA and protein molecules bound together, in this context referring to the Cas9 protein paired with its guide RNA that must maintain structural integrity for gene editing to work.
- Scavenger receptor-mediated endocytosis
- A cellular uptake pathway where cells internalize molecules by binding them to scavenger receptors on the cell surface, a mechanism that SNAs exploit and that is active across most mammalian cell types.
- Off-target editing
- Unintended genetic modifications at DNA sequences similar to but distinct from the intended target site, a safety concern in CRISPR therapy where rates above ~0.1% are typically considered unacceptable.
- Genodermatoses
- Genetic skin diseases caused by inherited mutations in genes affecting skin structure or function, representing a disease category that could be treated by improved CRISPR delivery to skin tissue.
What's your read?
Your read shapes future topic weighting.
Your vote feeds topic weights, community direction and future prioritisation. Open community direction
Sources
- Tier 3 Discovery broadens scope of use of CRISPR gene editing
- Tier 3 Biotechnology News -- ScienceDaily
- Tier 3 Colossal Biosciences announces ‘de-extinction’ plan for African bluebuck | CNN
- Tier 3 Clarkson University Researchers Contribute to Breakthrough Biosensor Technology Published in Nature Biotechnology | Clarkson University
- Tier 3 Biotech and Pharma Industry News | BioPharma Dive
- Tier 3 ScienceDaily: Your source for the latest research news
- Tier 3 Fierce Biotech News & Reports
- Tier 1 Nature Biotechnology
- Tier 3 2024 in science - Wikipedia
- Tier 3 Top Biotech Startups 2026: An Analysis of Emerging Trends | IntuitionLabs
- Tier 3 Study: CRISPR gene editing leads to improvements in vision for people with inherited blindness | Ophthalmology Times - Clinical Insights for Eye Specialists
- Tier 3 A one-time treatment tweaked their genes — and lowered their cholesterol
- Tier 3 Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing - Intellia Therapeutics
- Tier 3 Potential Cure for HIV from CRISPR Gene Editing in Phase 1/2 Clinical Trial | Contagion Live
- Tier 3 Milestone for Crispr: First-of-Its-Kind Gene Editing Treatment Successfully Passes Clinical Trial
- Tier 3 CRISPR gene editing - Wikipedia
- Tier 3 Intellia CRISPR drug succeeds in late-stage study against rare swelling disorder | BioPharma Dive
- Tier 3 Scientists just made CRISPR three times more effective | ScienceDaily
- Tier 3 Synthetic Biology Market Size, Share, Industry Growth 2035
- Tier 3 Synthetic Biology Market Size, Share & Growth Trends 2035
- Tier 3 Flagship Pioneering Launches Serif Biomedicines to Establish Modified DNA as a New Biotechnology
- Tier 3 SynbiTECH 2026 | The Must-Attend Synthetic Biology Conference
- Tier 3 2026 Synthetic Biology: Engineering, Evolution, & Design (SEED) | AIChE
- Tier 3 Synthetic Biology Market worth $31.52 billion in 2029 | Press Releases | reformer.com
- Tier 3 Synthetic Biology Market Analysis 2026-2031: Genome Engineering Accounts for 33.21% Share, with Asia-Pacific as the Fastest-Growing Region, Says Mordor Intelligence
- Tier 3 Global DNA Read, Write and Edit Market to Surge to $67.7 Billion by 2030, Driven by CRISPR Advances, Genomic Diagnostics and Expanding Clinical Applications
- Tier 3 North America Gene Synthesis Market Outlook 2026-2034
- Tier 3 Synthetic Biology Product Market is Going to Boom | Amyris , Zymergen
- Tier 3 List of Funded Biotech Startups (2026) - Fundraise Insider
- Tier 3 Early-stage funding slumps toward post-pandemic low, piling more pressure on biotech startups
- Tier 3 The Week’s 10 Biggest Funding Rounds: SiFive Leads With $400M For Custom Chip Designs As Aviation, Biotech And Defense Startups Also Raise Big
- Tier 3 1,200+ Funded Biotech Startups 2026 | Verified Contacts
- Tier 3 Biotech Valuation Benchmarks for Series A and B in 2026
- Tier 3 The Week’s 10 Biggest Funding Rounds: AI, Autonomy And Biotech Top The Ranks
- Tier 3 Biotechnology Startup Funding 2025-2026 – New Market Pitch
- Tier 3 Jeito Capital, prominent biotech investor, raises $1.2B for next fund | BioPharma Dive
- Tier 3 Stanford's James Zou targets $1B valuation for AI physiology startup backed by Nature-published research and FDA-cleared cardiac AI
- Tier 3 DNA origami vaccines could be the next leap beyond mRNA | ScienceDaily
- Tier 1 Engineered cells as programmable mRNA delivery vehicles | Nature Reviews Bioengineering
- Tier 3 AI, CRISPR, and mRNA Driving Biotech’s Smartest Decade Yet | BioPharm International
- Tier 3 New Research Challenges Understanding of mRNA Vaccines and Establishes Innovative Way to Make Them More Effective | Mount Sinai - New York
- Tier 3 mRNA Delivery Technology Landscape 2026 — PatSnap Eureka | PatSnap
- Tier 3 Next-generation neoantigen mRNA vaccines: Immuno-engineering strategies for precision cancer immunotherapy | Cellular Oncology | Springer Nature Link
- Tier 3 After a year of turmoil, cancer researchers see promising signs for mRNA vaccines | CNN
- Tier 3 mRNA Therapeutics Market Size to Hit USD 83.49 Billion by 2035 - BioSpace
- Tier 3 Next-generation neoantigen mRNA vaccines: Immuno-engineering strategies for precision cancer immunotherapy - PMC
Optional Submit a prediction Optional: add your prediction on the core question if you like.
Prediction
Will SNA-delivered CRISPR-Cas9 enter a human clinical trial within three years of this discovery?